文献速递骨质疏松与代谢性骨病

甲状旁腺激素(1-34)联合全身振动运动治疗绝经后骨质疏松的随机对照试验

The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.
PubMed 文献 · Osteoporos Int · 2019-07-15

PaVOS随机对照试验将35例开始特立帕肽20 μg/天的绝经后骨质疏松女性随机分为特立帕肽联合全身振动运动组(17例)与单用特立帕肽组(18例),比较12个月骨密度、骨微结构及骨转换标志物变化。联合组腰椎骨密度平均增加8.90%±5.47,单药组增加6.65%±5.51,联合全身振动运动的校正治疗效应为2.95%(95%CI 0.14-5.77;P=0.040),差异有统计学意义;两组骨转换标志物在3个月和6个月均显著升高且组间无显著差异,髋部骨密度、骨微结构参数及硬化蛋白水平未见其他治疗效应。

要点

  • 特立帕肽联合全身振动运动组12个月腰椎骨密度增加8.90%±5.47,单用特立帕肽组增加6.65%±5.51。
  • 联合全身振动运动的校正治疗效应为2.95%(95%CI 0.14-5.77;P=0.040),差异有统计学意义。
  • 两组骨转换标志物在3个月和6个月均显著升高,组间无显著差异。

核心结论

  • 在绝经后骨质疏松女性中,12个月全身振动运动联合特立帕肽相比单用特立帕肽对腰椎骨密度具有显著的临床相关治疗效应。

研究设计与样本

  • PaVOS研究为随机对照试验,绝经后骨质疏松女性开始特立帕肽20 μg/天治疗后随机分为全身振动运动联合特立帕肽组或单用特立帕肽组。
  • 全身振动运动为每周三次、每次12分钟(运动与休息时间比1:1)。
  • 共35例女性被随机分组,联合组17例,单用特立帕肽组18例。
  • 数据分析采用线性混合回归模型校正基线值或稳健聚类回归,按意向性治疗(ITT)分析。

主要发现

  • 12个月时两组腰椎骨密度均显著增加,联合组平均增加8.90%±5.47,单用特立帕肽组平均增加6.65%±5.51。
  • 联合全身振动运动的校正治疗效应为2.95%(95%CI 0.14-5.77;P=0.040),差异有统计学意义。
  • 两组骨转换标志物在3个月和6个月均显著升高,组间无显著差异。
  • 髋部骨密度、骨微结构参数及硬化蛋白水平均未观察到其他治疗效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Treatment effects of combining teriparatide and whole-body vibration exercise (WBV) vs teriparatide alone in twelve months were compared using bone mineral density (BMD), bone microarchitecture, and bone turnover markers. We found an increased effect in lumbar spine BMD by adding WBV to teriparatide in postmenopausal osteoporotic women. INTRODUCTION: The parathyroid hormone (PTH) analogue teriparatide is an effective but expensive anabolic treatment for osteoporosis. Whole-body vibration exercise (WBV) has been found to stimulate muscle and bone strength in some studies. Animal data demonstrate a beneficial effect on bone when combining PTH with mechanical loading. The aim of this study was to investigate if combining WBV exercise and teriparatide treatment gives additional beneficial effects on bone compared to teriparatide alone in postmenopausal women with osteoporosis. METHODS: The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone. WBV consisted of three sessions a week (12 min, including 1:1 ratio of exercise:rest). Bone mineral density (BMD) and bone microarchitecture, bone turnover markers, and sclerostin measurements were obtained. Data were analyzed using a linear mixed regression model with adjustment for baseline values or robust cluster regression in an intention-to-treat (ITT) analysis. RESULTS: Thirty-five women were randomized (17 in teriparatide + WBV group and 18 in teriparatide group). At 12 months, both groups increased significantly in BMD at the lumbar spine. The teriparatide + WBV group increased by (mean ± SD) 8.90% ± 5.47 and the teriparatide group by 6.65% ± 5.51. The adjusted treatment effect of adding WBV to teriparatide was statistically significant at 2.95% [95% CI = 0.14-5.77; P = 0.040]. Markers of bone turnover increased significantly in both groups at three and six months with no significant difference between groups. No other treatment effects were observed in hip BMD, bone microarchitecture parameters, or sclerostin levels in either group. CONCLUSION: Twelve months of WBV and teriparatide had a significant clinically relevant treatment effect in lumbar spine BMD compared to teriparatide alone in postmenopausal osteoporotic women. ClinicalTrials.gov :(NCT02563353).

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Jepsen DB, Ryg J, Hansen S, et al. The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial. Osteoporos Int. 2019. PMID: 31309239. doi:10.1007/s00198-019-05029-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。